Patrick Schlegel

Professor Schlegel is a clinician scientist specialised in advanced CAR-T cell technologies, and is currently a Professor and Head of Cellular Cancer Therapeutics – University of Sydney. He trained as a clinician scientist in Paediatric Haematology/Oncology, Stem Cell Transplantation and General Paediatrics at the University of Tübingen, Germany. His focus during clinical training being allogeneic haematopoietic stem cell transplantation (HSCT) with major interest in haploidentical stem cell transplantation and novel graft manipulation strategies.

His research includes transplant immunology with regard to humoral and cellular immunotherapy including the immune reconstitution of NK and gd T cells after haploidentical HSCT, innate immune mediated antitumour response utilising monoclonal antibodies and antibody constructs, immunomodulation as well as T cell-mediated anti-tumour response via immune vaccine and bispecific T cell engagers. Dr Schlegel has pioneered the use of the CAR-T technology with Biosceptre’s novel targeting system that has the potential to treat a broad range of cancers and is developing this technology further with Biosceptre.